Cargando…
Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony
PURPOSE OF REVIEW: Fibroblast growth factor 23 (FGF23) is a key phosphate-regulating hormone that has been associated with adverse outcomes in patients with chronic kidney disease (CKD). Emerging data suggest that FGF23 plays a specific role in type 2 diabetes, partly independent of kidney function....
Autores principales: | Yeung, Stanley M. H., Bakker, Stephan J. L., Laverman, Gozewijn D., De Borst, Martin H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455586/ https://www.ncbi.nlm.nih.gov/pubmed/32857288 http://dx.doi.org/10.1007/s11892-020-01335-7 |
Ejemplares similares
-
Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease
por: Hasegawa, Sho, et al.
Publicado: (2021) -
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022) -
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018) -
The Landscape of Diabetic Kidney Disease in the United States
por: Duru, O. Kenrik, et al.
Publicado: (2018) -
Physical Activity in the Prevention of Development and Progression of Kidney Disease in Type 1 Diabetes
por: Pongrac Barlovic, Drazenka, et al.
Publicado: (2019)